Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
Earnings Data
Report Date
Feb 12, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
1.32Last Year’s EPS
-0.65Same Quarter Last Year
Strong Buy
Based on 24 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in the TTR franchise and strong pipeline advancements, with increased financial guidance indicating confidence in future performance. However, challenges remain with decreased gross margins and increased expenses, along with ongoing pricing negotiations in Europe.Company Guidance
Record Growth in TTR Franchise Revenues
The TTR franchise revenues reached $724 million, showing 135% year-over-year growth, largely driven by the AMVUTTRA CM launch in the U.S., with a 194% year-over-year increase.
Global Commercial Success
Alnylam delivered $851 million in combined net product revenues, representing 103% growth year-over-year and 27% growth from the previous quarter.
Pipeline Advancements
Initiation of two new Phase III trials: ZENITH Phase III cardiovascular outcomes trial for zilebesiran in hypertension and TRITON-PN study for nucresiran in hATTR-PN.
Financial Performance and Guidance Increase
Total net product revenues for 2025 were increased to a range of $2.95 billion to $3.05 billion, representing a $275 million or 10% increase at the midpoint.
Expansion and Adoption of AMVUTTRA
The AMVUTTRA ATTR-CM launch doubled patient demand, and the health system setup is complete in nearly all priority health systems.
ALNY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ALNY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 30, 2025 | $481.59 | $449.56 | -6.65% |
Jul 31, 2025 | $339.80 | $392.24 | +15.43% |
May 01, 2025 | $263.24 | $255.13 | -3.08% |
Feb 13, 2025 | $265.96 | $264.89 | -0.40% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Alnylam Pharmaceuticals (ALNY) report earnings?
Alnylam Pharmaceuticals (ALNY) is schdueled to report earning on Feb 12, 2026, Before Open (Confirmed).
What is Alnylam Pharmaceuticals (ALNY) earnings time?
Alnylam Pharmaceuticals (ALNY) earnings time is at Feb 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALNY EPS forecast?
ALNY EPS forecast for the fiscal quarter 2025 (Q4) is 1.32.